Related Experiment Video
Updated: Jan 2, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
The Long Non-Coding RNA SBF2-AS1 Exerts Oncogenic Functions In Gastric Cancer By Targeting The miR-302b-3p/E2F
Chaojie Liang1, Chaosen Yue2, Chaowei Liang1
1Department of General Surgery, First Hospital/First Clinical Medical College of Shanxi Medical University, Taiyuan, Shanxi 030001, People's Republic of China.
Background And Aims:
Studies show that the long non-coding RNA, SBF2-AS1, plays a critical role in cancer progression, but the role of SBF2-AS1 in gastric cancer has not been reported. Therefore, this study aimed to elucidate the mechanism of SBF2-AS1 in gastric cancer (GC).
Methods:
A meta-analysis, based on the gene expression omnibus database and TCGA dataset was performed to explore the prognostic value of SBF2-AS1 in GC. RT-PCR was also conducted to investigate the clinicopathologic value of SBF2-AS1 in GC. The effect of SBF2-AS1 in GC cell lines was conducted by gain or loss-of-function assays, and the SBF2-AS1 target gene was confirmed using a luciferase reporter assay and bioinformatics.
Results:
SBF2-AS1 was overexpressed in GC tissues and cell lines, and SBF2-AS1 overexpression indicated poor overall survival and could serve as an independent prognostic factor. Moreover, knockdown of SBF2-AS1 inhibited cell growth, invasion, and metastasis, promoted apoptosis, and caused cell cycle arrest. Luciferase reporter and gain- or loss-of-function assays indicated that SBF2-AS1 acted as a competing endogenous (ceRNA) for microRNA (miR)-302b-3p, which blocked the inhibitory effect of miR-302b-3p on the E2F transcription factor 3 (E2F3).
Conclusion:
SBF2-AS1 could be a potential diagnostic and prognostic biomarker in GC, and SBF2-AS1 accelerates tumor progression via the miR-302b-3p/E2F3 axis.
Insights
The long non-coding RNA SBF2-AS1 is overexpressed in gastric cancer (GC), promoting tumor progression. Targeting SBF2-AS1 may offer a new diagnostic and prognostic strategy for GC patients.
Area of Science:
- Molecular Oncology
- Cancer Genomics
Background:
- Long non-coding RNA SBF2-AS1 is implicated in cancer progression.
- Its specific role in gastric cancer (GC) remains largely unexplored.
Purpose of the Study:
- To investigate the mechanism of SBF2-AS1 in gastric cancer.
- To evaluate SBF2-AS1 as a diagnostic and prognostic biomarker for GC.
Main Methods:
- Meta-analysis of public datasets (GEO, TCGA) for prognostic value.
- RT-PCR for clinicopathologic correlation.
- In vitro gain/loss-of-function assays in GC cell lines.
- Luciferase reporter and bioinformatics for target validation.
Main Results:
- SBF2-AS1 is significantly overexpressed in GC tissues and cell lines.
- High SBF2-AS1 expression correlates with poor overall survival and serves as an independent prognostic factor.
- SBF2-AS1 knockdown inhibits GC cell growth, invasion, and metastasis while promoting apoptosis and cell cycle arrest.
- SBF2-AS1 functions as a competing endogenous RNA (ceRNA) for miR-302b-3p, thereby inhibiting miR-302b-3p's suppression of E2F3.
Conclusions:
- SBF2-AS1 is a potential diagnostic and prognostic biomarker for gastric cancer.
- SBF2-AS1 promotes GC progression through the miR-302b-3p/E2F3 signaling axis.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Abnormal Proliferation
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...